The European Society of Medical Oncology (ESMO) 2021 guidelines [35] state that locoregional treatment could be considered for asymptomatic women aged < 55 years with hormone receptor-positive HER2-negative bone oligometastatic breast cancer after a good response to initial systemic treatment. This evidence concerns the gene NR4A1 and breast cancer.